Market closed
Blueprint Medicines/$BPMC
Blueprint Medicines shares are trading higher after the company raised its Ayvakit sales guidance for 2025, despite reporting lower-than-expected Q1 earnings.
6 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Blueprint Medicines
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Ticker
$BPMC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
649
Website
BPMC Metrics
BasicAdvanced
$6.4B
-
-$1.07
0.62
-
Price and volume
Market cap
$6.4B
Beta
0.62
52-week high
$121.90
52-week low
$73.04
Average daily volume
1.1M
Financial strength
Current ratio
2.848
Quick ratio
2.658
Long term debt to equity
202.691
Total debt to equity
242.506
Interest coverage (TTM)
-3.08%
Management effectiveness
Return on assets (TTM)
-11.89%
Return on equity (TTM)
-31.26%
Valuation
Price to revenue (TTM)
12.261
Price to book
21.17
Price to tangible book (TTM)
21.17
Price to free cash flow (TTM)
-31.633
Growth
Revenue change (TTM)
104.04%
Earnings per share change (TTM)
-87.25%
3-year revenue growth (CAGR)
41.37%
3-year earnings per share growth (CAGR)
-54.06%
What the Analysts think about BPMC
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Blueprint Medicines stock.
BPMC Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BPMC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BPMC News
AllArticlesVideos
Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript
Seeking Alpha·1 day ago
Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth
Seeking Alpha·4 weeks ago
Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript
Seeking Alpha·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Blueprint Medicines stock?
Blueprint Medicines (BPMC) has a market cap of $6.4B as of May 03, 2025.
What is the P/E ratio for Blueprint Medicines stock?
The price to earnings (P/E) ratio for Blueprint Medicines (BPMC) stock is 0 as of May 03, 2025.
Does Blueprint Medicines stock pay dividends?
No, Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders as of May 03, 2025.
When is the next Blueprint Medicines dividend payment date?
Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders.
What is the beta indicator for Blueprint Medicines?
Blueprint Medicines (BPMC) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.